589 related articles for article (PubMed ID: 20421545)
1. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors.
Lee JS; Leem SH; Lee SY; Kim SC; Park ES; Kim SB; Kim SK; Kim YJ; Kim WJ; Chu IS
J Clin Oncol; 2010 Jun; 28(16):2660-7. PubMed ID: 20421545
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
3. Re: Expression Signature of E2F1 and its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors.
Wood DP
J Urol; 2011 Feb; 185(2):469-70. PubMed ID: 22088627
[No Abstract] [Full Text] [Related]
4. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
[TBL] [Abstract][Full Text] [Related]
5. Differential PTEN protein expression profiles in superficial versus invasive bladder cancers.
Koksal IT; Yasar D; Dirice E; Usta MF; Karauzum S; Luleci G; Baykara M; Sanlioglu S
Urol Int; 2005; 75(2):102-6. PubMed ID: 16123561
[TBL] [Abstract][Full Text] [Related]
6. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
7. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
8. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
9. Carcinoma in a bladder diverticulum: presentation and treatment outcome.
Golijanin D; Yossepowitch O; Beck SD; Sogani P; Dalbagni G
J Urol; 2003 Nov; 170(5):1761-4. PubMed ID: 14532771
[TBL] [Abstract][Full Text] [Related]
10. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
11. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
12. Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods.
Matsumoto K; Kikuchi E; Horiguchi Y; Tanaka N; Miyajima A; Nakagawa K; Nakashima J; Oya M
Urology; 2010 Jun; 75(6):1385-90. PubMed ID: 20110108
[TBL] [Abstract][Full Text] [Related]
13. Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.
Bartsch G; Mitra AP; Mitra SA; Almal AA; Steven KE; Skinner DG; Fry DW; Lenehan PF; Worzel WP; Cote RJ
J Urol; 2016 Feb; 195(2):493-8. PubMed ID: 26459038
[TBL] [Abstract][Full Text] [Related]
14. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
15. A molecular signature in superficial bladder carcinoma predicts clinical outcome.
Dyrskjøt L; Zieger K; Kruhøffer M; Thykjaer T; Jensen JL; Primdahl H; Aziz N; Marcussen N; Møller K; Orntoft TF
Clin Cancer Res; 2005 Jun; 11(11):4029-36. PubMed ID: 15930337
[TBL] [Abstract][Full Text] [Related]
16. CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder.
Choi JW; Kim Y; Lee JH; Kim YS
Int J Urol; 2013 Feb; 20(2):251-5. PubMed ID: 22905972
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
18. Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999-2001 registry in Japan.
Okajima E; Fujimoto H; Mizutani Y; Kikuchi E; Koga H; Hinotsu S; Shinohara N; Miki T;
Int J Urol; 2010 Nov; 17(11):905-12. PubMed ID: 20969637
[TBL] [Abstract][Full Text] [Related]
19. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
20. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]